The present invention discloses a process for the therapeutic management ofdiarrheapredominant irritable bowel syndrome in humans comprising the oraladministration of Bacilluscoagulans SBC37-01, MTCC 5856 (containing not less than 2 billion spores)along withstandard treatment of care in a specific manner.